Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group, Peter W Horby, Marion Mafham, Leon Peto, Mark Campbell, Guilherme Pessoa-Amorim, Enti Spata, Natalie Staplin, Jonathan R Emberson, Benjamin Prudon, Paul Hine, Thomas Brown, Christopher A Green, Rahuldeb Sarkar, Purav Desai, Bryan Yates, Tom Bewick, Simon Tiberi, Tim Felton, J Kenneth Baillie, Maya H Buch, Lucy C Chappell, Jeremy N Day, Saul N Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, David M Weinreich, Richard Haynes, Martin J Landray
doi: https://doi.org/10.1101/2021.06.15.21258542

Article Information

doi 
https://doi.org/10.1101/2021.06.15.21258542
History 
  • June 16, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. RECOVERY Collaborative Group*,
  2. Peter W Horby1,&,
  3. Marion Mafham2,
  4. Leon Peto2,
  5. Mark Campbell2,
  6. Guilherme Pessoa-Amorim2,
  7. Enti Spata3,
  8. Natalie Staplin3,
  9. Jonathan R Emberson3,
  10. Benjamin Prudon4,
  11. Paul Hine5,
  12. Thomas Brown6,
  13. Christopher A Green7,
  14. Rahuldeb Sarkar8,
  15. Purav Desai9,
  16. Bryan Yates10,
  17. Tom Bewick11,
  18. Simon Tiberi12,
  19. Tim Felton13,
  20. J Kenneth Baillie14,
  21. Maya H Buch15,
  22. Lucy C Chappell16,
  23. Jeremy N Day17,
  24. Saul N Faust18,
  25. Thomas Jaki19,
  26. Katie Jeffery20,
  27. Edmund Juszczak21,
  28. Wei Shen Lim22,
  29. Alan Montgomery21,
  30. Andrew Mumford23,
  31. Kathryn Rowan24,
  32. Guy Thwaites17,
  33. David M Weinreich25,
  34. Richard Haynes3 and
  35. Martin J Landray2,&
  1. 1Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  2. 2Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
  3. 3MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
  4. 4North Tees and Hartlepool NHS Foundation Trust, Hartlepool, United Kingdom
  5. 5Liverpool University Hospitals NHS Foundation Trust
  6. 6Portsmouth Hospitals University NHS Foundation Trust, Portsmouth, United Kingdom
  7. 7University Hospitals Birmingham NHS Foundation Trust
  8. 8Medway NHS Foundation Trust
  9. 9Calderdale and Huddersfield NHS Foundation Trust
  10. 10Northumbria Healthcare NHS Foundation Trust
  11. 11University Hospitals Of Derby and Burton NHS Foundation Trust
  12. 12Barts Health NHS Trust
  13. 13Manchester University NHS Foundation Trust
  14. 14Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom
  15. 15Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
  16. 16School of Life Sciences, Kings College London, London, United Kingdom
  17. 17Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom
  18. 18NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom
  19. 19Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom
  20. 20Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
  21. 21School of Medicine, University of Nottingham, Nottingham, United Kingdom
  22. 22Respiratory Medicine Department, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom
  23. 23School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
  24. 24Intensive Care National Audit and Research Centre, London, United Kingdom
  25. 25Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA
  1. ↵&Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom., Email: recoverytrial{at}ndph.ox.ac.uk
Back to top
Posted June 16, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, Peter W Horby, Marion Mafham, Leon Peto, Mark Campbell, Guilherme Pessoa-Amorim, Enti Spata, Natalie Staplin, Jonathan R Emberson, Benjamin Prudon, Paul Hine, Thomas Brown, Christopher A Green, Rahuldeb Sarkar, Purav Desai, Bryan Yates, Tom Bewick, Simon Tiberi, Tim Felton, J Kenneth Baillie, Maya H Buch, Lucy C Chappell, Jeremy N Day, Saul N Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, David M Weinreich, Richard Haynes, Martin J Landray
medRxiv 2021.06.15.21258542; doi: https://doi.org/10.1101/2021.06.15.21258542
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area